Cargando…

索拉非尼联合CHAG方案诱导治疗10例FLT3-ITD突变阳性急性髓系白血病患者疗效观察

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348308/
https://www.ncbi.nlm.nih.gov/pubmed/27210879
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.05.013
_version_ 1783556784784408576
collection PubMed
description
format Online
Article
Text
id pubmed-7348308
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73483082020-07-16 索拉非尼联合CHAG方案诱导治疗10例FLT3-ITD突变阳性急性髓系白血病患者疗效观察 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2016-05 /pmc/articles/PMC7348308/ /pubmed/27210879 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.05.013 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 短篇论著
索拉非尼联合CHAG方案诱导治疗10例FLT3-ITD突变阳性急性髓系白血病患者疗效观察
title 索拉非尼联合CHAG方案诱导治疗10例FLT3-ITD突变阳性急性髓系白血病患者疗效观察
title_full 索拉非尼联合CHAG方案诱导治疗10例FLT3-ITD突变阳性急性髓系白血病患者疗效观察
title_fullStr 索拉非尼联合CHAG方案诱导治疗10例FLT3-ITD突变阳性急性髓系白血病患者疗效观察
title_full_unstemmed 索拉非尼联合CHAG方案诱导治疗10例FLT3-ITD突变阳性急性髓系白血病患者疗效观察
title_short 索拉非尼联合CHAG方案诱导治疗10例FLT3-ITD突变阳性急性髓系白血病患者疗效观察
title_sort 索拉非尼联合chag方案诱导治疗10例flt3-itd突变阳性急性髓系白血病患者疗效观察
topic 短篇论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348308/
https://www.ncbi.nlm.nih.gov/pubmed/27210879
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.05.013
work_keys_str_mv AT suǒlāfēiníliánhéchagfāngànyòudǎozhìliáo10lìflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìnghuànzhěliáoxiàoguānchá
AT suǒlāfēiníliánhéchagfāngànyòudǎozhìliáo10lìflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìnghuànzhěliáoxiàoguānchá
AT suǒlāfēiníliánhéchagfāngànyòudǎozhìliáo10lìflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìnghuànzhěliáoxiàoguānchá
AT suǒlāfēiníliánhéchagfāngànyòudǎozhìliáo10lìflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìnghuànzhěliáoxiàoguānchá
AT suǒlāfēiníliánhéchagfāngànyòudǎozhìliáo10lìflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìnghuànzhěliáoxiàoguānchá
AT suǒlāfēiníliánhéchagfāngànyòudǎozhìliáo10lìflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìnghuànzhěliáoxiàoguānchá
AT suǒlāfēiníliánhéchagfāngànyòudǎozhìliáo10lìflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìnghuànzhěliáoxiàoguānchá
AT suǒlāfēiníliánhéchagfāngànyòudǎozhìliáo10lìflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìnghuànzhěliáoxiàoguānchá
AT suǒlāfēiníliánhéchagfāngànyòudǎozhìliáo10lìflt3itdtūbiànyángxìngjíxìngsuǐxìbáixuèbìnghuànzhěliáoxiàoguānchá